Wiriyaporn Ridtitid, Julalak Karuehardsuwan, Natee Faknak, Panida Piyachaturawat, Phuphat Vongwattanakit, Santi Kulpatcharapong, Phonthep Angsuwatcharakon, Parit Mekaroonkamol, Pradermchai Kongkam, Rungsun Rerknimitr
BACKGROUND AND AIMS: Endoscopic transpapillary gallbladder stenting (ETGS) has been proposed as one of the adjunctive treatments, apart from antibiotics, before surgery in patients with acute cholecystitis whose cholecystectomy could not be performed or deferred. Currently, there are no comparative data on the outcomes of ETGS in those who receive and do not receive ETGS. We aimed to compare the rates of recurrent cholecystitis at 3 and 6 months in these two groups. METHODS: Between 2020-2023, eligible acute-calculous-cholecystitis patients with a high probability of common bile duct (CBD) stone, who were surgical candidates but could not have an early cholecystectomy during COVID-19 surgical lockdown, were randomized into groups A (received ETGS) and B (did not receive ETGS)...
February 13, 2024: Gastroenterology